

Supplementary Table 5. Adverse events in 15% or more of participants up to month 24 by age group

	<u>ATG</u> <u>Participants</u> 12-21 (n=26)	<u>Events</u>	<u>ATG</u> <u>Participants</u> 22-35 (n=12)	<u>Events</u>	<u>Placebo</u> <u>Participants</u> 12-21 (n=12)	<u>Events</u>	<u>Placebo</u> <u>Participants</u> 22-35 (n=8)	<u>Events</u>
Total Number of Adverse Events	688		460		259		156	
Grade 1	26 (100%)	217	12 (100%)	133	11 (91.7%)	107	7 (87.5%)	72
Grade 2	25 (96.2%)	348	12 (100%)	256	10 (83.3%)	122	8 (100%)	78
Grade 3	19 (73.1%)	61	12 (100%)	51	9 (75.0%)	25	3 (37.5%)	5
Grade 4	26 (100%)	59	12 (100%)	19	3 (25.0%)	4	1 (12.5%)	1
Grade 5	0	0	0	0	0 (0%)	0	0	0
Metabolism and nutrition disorders	23 (88.5%)	284	12 (100%)	229	9 (75.0%)	127	7 (87.5%)	79
Hypoglycaemia	20 (76.9%)	268	12 (100%)	227	9 (75.0%)	122	7 (87.5%)	79
Hyperglycaemia	7 (26.9%)	11	1 (8.3%)	1	1 (8.3%)	4	0	0
Infections and infestations	19 (73.1%)	51	10 (83.3%)	37	9 (75.0%)	23	5 (62.5%)	10
Upper respiratory tract infection	11 (42.3%)	22	5 (41.7%)	10	4 (33.3%)	12	3 (37.5%)	4
Viral infection	4 (15.4%)	9	1 (8.3%)	2	2 (16.7%)	2	1 (12.5%)	1
Blood and lymphatic system disorders	26 (100%)	80	12 (100%)	43	2 (16.7%)	4	2 (25.0%)	2
CD4 lymphocytes decreased	26 (100%)	26	12 (100%)	12	0 (0%)	0	0	0
Lymphopenia	26 (100%)	31	12 (100%)	17	0 (0%)	0	0	0
Leukopenia	10 (38.5%)	13	4 (33.3%)	7	0 (0%)	0	0	0
Neutropenia	6 (23.1%)	6	3 (25.0%)	4	1 (8.3%)	3	1 (12.5%)	1
Immune system disorders	26 (100%)	56	12 (100%)	28	1 (8.3%)	1	2 (25.0%)	2
Cytokine release syndrome	25 (96.2%)	25	12 (100%)	12	1 (8.3%)	1	0	0
Serum sickness	26 (100%)	27	12 (100%)	12	0 (0%)	0	0	0
Seasonal allergy	4 (15.4%)	4	3 (25.0%)	4	0 (0%)	0	2 (25.0%)	2
Skin and subcutaneous tissue disorders	17 (65.4%)	25	9 (75.0%)	19	6 (50.0%)	21	4 (50.0%)	5
Rash	2 (7.7%)	3	5 (41.7%)	5	1 (8.3%)	2	1 (12.5%)	1
Acne	7 (26.9%)	8			1 (8.3%)	1		
Pruritus	2 (7.7%)	2	2 (16.7%)	2	1 (8.3%)	1	2 (25.0%)	3
Dermatitis contact	1 (3.8%)	1	1 (8.3%)	1	2 (16.7%)	2	1 (12.5%)	1
Gastrointestinal disorders	18 (69.2%)	33	6 (50.0%)	18	6 (50.0%)	8	5 (62.5%)	12
Nausea	5 (19.2%)	5	2 (16.7%)	3	3 (25.0%)	4	2 (25.0%)	3
Diarrhoea	4 (15.4%)	4	1 (8.3%)	1	1 (8.3%)	1	2 (25.0%)	2
Vomiting	3 (11.5%)	4	0	0	1 (8.3%)	1	2 (25.0%)	2
Dyspepsia	1 (3.8%)	1	1 (8.3%)	1	1 (8.3%)	1	2 (25.0%)	2
Nervous system disorders	16 (61.5%)	21	8 (66.7%)	20	7 (58.3%)	17	4 (50.0%)	6
Headache	11 (42.3%)	14	7 (58.3%)	11	7 (58.3%)	11	3 (37.5%)	4
General disorders and administration site conditions	17 (65.4%)	19	9 (75.0%)	17	4 (33.3%)	9	4 (50.0%)	9

Fatigue	1 (3.8%)	1	2 (16.7%)	3	2 (16.7%)	3	2 (25.0%)	2
Pyrexia	5 (19.2%)	5	1 (8.3%)	1	0 (0%)	0	1 (12.5%)	1
Influenza like illness	0 (0%)	0	2 (16.7%)	2	1 (8.3%)	1	2 (25.0%)	2
Respiratory, thoracic and mediastinal disorders	18 (69.2%)	34	5 (41.7%)	8	7 (58.3%)	16	4 (50.0%)	10
Oropharyngeal pain	7 (26.9%)	10	2 (16.7%)	3	3 (25.0%)	4	2 (25.0%)	2
Cough	7 (26.9%)	9	1 (8.3%)	1	2 (16.7%)	2	2 (25.0%)	3
Nasal congestion	2 (7.7%)	3	1 (8.3%)	1	1 (8.3%)	2	2 (25.0%)	2
Rhinorrhoea	1 (3.8%)	1	0	0	2 (16.7%)	2	1 (12.5%)	1
Musculoskeletal and connective tissue disorders	11 (42.3%)	16	3 (25.0%)	10	6 (50.0%)	10	5 (62.5%)	10
Back pain	2 (7.7%)	2	2 (16.7%)	3	1 (8.3%)	1	4 (50.0%)	5
Arthralgia	4 (15.4%)	4	0	0	3 (25.0%)	4	0	0
Musculoskeletal pain	1 (3.8%)	1	0	0	0 (0%)	0	3 (37.5%)	3
Psychiatric disorders	7 (26.9%)	13	2 (16.7%)	2	7 (58.3%)	12	0	0
Depression	4 (15.4%)	7	0	0	4 (33.3%)	4	0	0
Vascular disorders	4 (15.4%)	6	0	0	3 (25.0%)	3	2 (25.0%)	2
Hypotension	0 (0%)	0	0	0	1 (8.3%)	1	2 (25.0%)	2